Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Part A: AZD9833 monotherapy dose escalation.

Part B: AZD9833 monotherapy expansion.

Part C: AZD9833 in combination with palbociclib dose escalation

Part D: AZD9833 in combination with palbociclib expansion

Part E: AZD9833 in combination with everolimus dose escalation

Part F: AZD9833 in combination with everolimus dose expansion

Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation

Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion

Part I: AZD9833 in combination with capivasertib dose escalation

Part J: AZD9833 in combination with capivasertib dose expansion

Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation

Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion

Part M: AZD9833 in combination with anastrozole dose escalation

Part N: AZD9833 in combination with anastrozole dose expansion